Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors.

IF 1.5 4区医学 Q3 DERMATOLOGY

Melanoma Research Pub Date : 2024-04-22 DOI:10.1097/cmr.0000000000000972

Yao Gao, Yao Wang, Yueyue Luo, Yong Zhang, Saiqi Wang, Xiance Tang, Peng Qin, Benling Xu, Quanli Gao, Tiepeng Li

引用次数: 0

Abstract

The aim of this study is to determine whether the pretreatment CD8+PD-1+ to CD4+PD-1+ (PERLS) ratio is an independent risk prognostic factor of advanced melanoma patients. We retrospectively analyzed the efficacy and flow cytometry data from advanced melanoma patients who received PD-1 inhibitor as monotherapy between January 1, 2018 and January 26, 2022. Fifty-nine patients were enrolled, the PERLS cutoff was 1.125. PERLS did not correlate with clinical characteristics but were significantly associated with baseline CD8+, CD4+, and CD8+PD-1+ T cells. The mean overall survival and the progression-free survival were 45.8 and 17.1 months for the low PERLS group (n = 39), compared with 29.9 (P = 0.001) and 9.7 (P = 0.003) months for the high PERLS group (n = 20), respectively. Pretreatment PERLS might contribute to selecting patients before receiving anti-PD-1 therapy.

查看原文本刊更多论文

治疗前 CD8+PD-1+ 与 CD4+PD-1+ 的比率与接受 PD-1 抑制剂治疗的晚期黑色素瘤患者的预后有关。

本研究旨在确定治疗前CD8+PD-1+与CD4+PD-1+（PERLS）的比值是否是晚期黑色素瘤患者的独立风险预后因素。我们回顾性分析了2018年1月1日至2022年1月26日期间接受PD-1抑制剂单药治疗的晚期黑色素瘤患者的疗效和流式细胞术数据。59名患者入组，PERLS临界值为1.125。PERLS与临床特征无关，但与基线CD8+、CD4+和CD8+PD-1+ T细胞显著相关。低 PERLS 组（39 人）的平均总生存期和无进展生存期分别为 45.8 个月和 17.1 个月，而高 PERLS 组（20 人）的平均总生存期和无进展生存期分别为 29.9 个月（P = 0.001）和 9.7 个月（P = 0.003）。治疗前PERLS可能有助于在接受抗PD-1治疗前选择患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Research 医学-皮肤病学

CiteScore

3.40

自引率

4.50%

发文量

139

审稿时长

6-12 weeks

期刊介绍： Melanoma Research is a well established international forum for the dissemination of new findings relating to melanoma. The aim of the Journal is to promote the level of informational exchange between those engaged in the field. Melanoma Research aims to encourage an informed and balanced view of experimental and clinical research and extend and stimulate communication and exchange of knowledge between investigators with differing areas of expertise. This will foster the development of translational research. The reporting of new clinical results and the effect and toxicity of new therapeutic agents and immunotherapy will be given emphasis by rapid publication of Short Communications. Thus, Melanoma Research seeks to present a coherent and up-to-date account of all aspects of investigations pertinent to melanoma. Consequently the scope of the Journal is broad, embracing the entire range of studies from fundamental and applied research in such subject areas as genetics, molecular biology, biochemistry, cell biology, photobiology, pathology, immunology, and advances in clinical oncology influencing the prevention, diagnosis and treatment of melanoma.